Bayer Animal Health Links With Pharmaron
Bayer has entered a partnership with Pharmaron to jointly develop new molecular entities for veterinary medicines. The pact gives the German group a chance to fully leverage the contract drug development’s Chemistry, Manufacturing and Controls (CMC) service platform.
Financial terms of the arrangement that includes drug substance and drug product manufacturing to support Bayer’s research, development and commercialization needs, were not disclosed.
Pharmaron will provide state-of-the-art CMC capabilities and resources to accelerate the development of preclinical and clinical projects for Bayer Animal Health, and Bayer said the partnership will facilitate the exploration of the small molecule-based chemical space, to uncover a variety of future therapeutic options for diseases that still cannot be adequately treated today.
“By combining the know-how and capabilities from an industry leading Contract Development & Manufacturing Organization like Pharmaron with high quality innovation projects derived from Bayer’s research, we will reduce our time to market and increase our success rate to deliver our development portfolio to the market,” said Douglas Hutchens Bayer Animal Health’s chief veterinary officer as well as head of drug discovery.
